[PDF] Top 20 Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
Has 10000 "Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis" found on our website. Below are the top 20 most common "Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis".
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
... β 1b was given subcutaneously (250 µ g or 50 µ g every second day) to 372 patients with EDSS score less than ...β 1b reduced relapses (but only when given in higher dose – 250 µ g) for 34% ...β 1b) ... See full document
7
Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
... Abstract: Interferon beta-1a is available as an immunomodulating agent for relapsing forms of multiple ...undergoing treatment with interferon beta-1a for ... See full document
6
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
... the treatment is started with basic therapeutics and the patient is mon- itored clinically with subsequent magnetic resonance imaging ...tolerated treatment, the therapy is ...include interferon-β ... See full document
9
PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
... IFN beta BaroFeron™, demonstrating acceptable levels of safety and tolerability compared to the marketed ...PEG-IFN beta-1b NU400 derived from aggregate-free IFN NU100 (identical to BaroFeron™) and ... See full document
8
The assessment for disinvestment of intramuscular interferon beta for relapsing-remitting multiple sclerosis in Brazil
... was treatment failure, identified by treatment switching or relapse treatment or death, whichever occurred ...their treatment or interrupted their treatment for 4 or more months ... See full document
13
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
... dosage of 44 µg administered by SC injections TIW (TIW) with a dosage of 30 µg administered by IM injections QW over 1 year (Table 2). The primary outcome was the proportion of patients remaining relapse free, which ... See full document
14
Autoinjector preference among patients with multiple sclerosis: results from a national survey
... Despite oral therapies in MS, injectable treatment options like the beta interferons for s.c. administration, have an important value in the MS therapy algorithm and will con- tinue to cover ... See full document
10
Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort<sup>®</sup> devices
... eligible injectable disease- modifying therapies, glatiramer acetate was used most commonly (85 [42%]); there were 67 ...receiving interferon beta-1b, of whom 16 were receiving Extavia ® ... See full document
8
Serial whole brain magnetization transfer imaging in patients with relapsing remitting multiple sclerosis at baseline and during treatment with interferon beta 1b
... The results of our whole-brain histographic analysis confirm the previous findings of van Buchem et al (17, 18) that the MTR histographic peak and mean are decreased in patients with relapsing-remitting MS ... See full document
9
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
... pipeline to 2D images, given their availability in this retrospective study and our previous demonstration that these images showed 1) sensitivity to disease-specific ef- fects and 2) high reproducibility [29]. We did ... See full document
8
SWiss Atorvastatin and Interferon Beta 1b Trial In Multiple Sclerosis (SWABIMS) rationale, design and methodology
... sclerosis that would better explain the patient's signs and symptoms, uncontrolled medical or psychiatric condi- tions, drug abuse, previous therapy at any time with mon- oclonal antibodies, mitoxantrone, ... See full document
7
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
... early treatment group gained ...early treatment group (estimated conversion rate ...(ie, interferon beta-1b drug costs, costs for inpatient and outpatient care, and costs related to ... See full document
11
Early stage and long term treatment of multiple sclerosis with interferon-β
... were found to be younger, to have higher relapse rates prior to entry, shorter disease duration, and a higher proportion of contrast enhancing lesions. The entry criteria for these two studies may have added to the ... See full document
15
Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
... vs. relapsing remitting, RR), relapse rate in the two years preceding the study entry, EDSS, BDI, FSS, MMSE-c and IFN- β treatment (IFN-β treated ...of treatment group over the time were also ... See full document
7
Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials
... number of recurrences in the year preceding the study, which was one of the important covariates. The hazard ratio (relapse rate ratio) of the active group to the placebo group was set at 1/1.3, such the true value of ... See full document
6
Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta 1b therapy
... CD80 is a critical costimulatory molecule for development of inflammatory brain disease. It is required for induction of active EAE (8), and EAE-susceptible SJL mice express more CD80 than EAE-resistant B6 mice (16). ... See full document
9
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
... GA treatment group than in the IFN β -1b 250 µ g group, but in the same way, the incidence of this reactions decreased over the ...to treatment was also assessed demonstrating that the adherence to ... See full document
8
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
... IFN beta has a good safety profile, with no major adverse events, and is generally well ...IFN beta treatment, and elevated liver enzymes have been ... See full document
8
Emerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosis
... in Multiple Sclerosis (ECTRIMS) meet- ing in ...with relapsing MS already on a stable dose of IFN- β ...β 1b (250 μ g subcutaneously every other ...the interferon-based treatment ... See full document
14
Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
... Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most ... See full document
8
Related subjects